HomeCompareAVTE vs PM

AVTE vs PM: Dividend Comparison 2026

AVTE yields 74.63% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVTE wins by $1.25M in total portfolio value
10 years
AVTE
AVTE
● Live price
74.63%
Share price
$2.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.30M
Annual income
$358,033.82
Full AVTE calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — AVTE vs PM

📍 AVTE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVTEPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVTE + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVTE pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVTE
Annual income on $10K today (after 15% tax)
$6,343.28/yr
After 10yr DRIP, annual income (after tax)
$304,328.75/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, AVTE beats the other by $302,201.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVTE + PM for your $10,000?

AVTE: 50%PM: 50%
100% PM50/50100% AVTE
Portfolio after 10yr
$675.7K
Annual income
$180,268.22/yr
Blended yield
26.68%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

AVTE
Analyst Ratings
2
Buy
6
Hold
Consensus: Hold
Price Target
$13.00
+385.1% upside vs current
Range: $2.00 — $35.00
Altman Z
2.1
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVTE buys
0
PM buys
5
PoliticianChamberTickerTypeAmountDate
Julia Letlow🏢 House$PM▼ Sell$1,001 - $15,0002026-02-05
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$PM▼ Sell$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$PM▼ Sell$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$PM▲ Buy$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$PM▲ Buy$15,001 - $50,0002025-09-05
Ro Khanna🏢 House$PM▲ Buy$15,001 - $50,0002025-08-26
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-08-14
Julie Johnson🏢 House$PM▼ Sell$1,001 - $15,0002025-07-22
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVTEPM
Forward yield74.63%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$1.30M$49.6K
Annual income after 10y$358,033.82$2,502.61
Total dividends collected$1.12M$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$13.00$194.30

Year-by-year: AVTE vs PM ($10,000, DRIP)

YearAVTE PortfolioAVTE Income/yrPM PortfolioPM Income/yrGap
1← crossover$18,163$7,462.69$11,650$409.56+$6.5KAVTE
2$32,102$12,667.52$13,592$497.49+$18.5KAVTE
3$55,273$20,924.46$15,882$605.21+$39.4KAVTE
4$92,813$33,671.17$18,589$737.41+$74.2KAVTE
5$152,151$52,841.00$21,794$899.94+$130.4KAVTE
6$243,759$80,956.60$25,597$1,100.16+$218.2KAVTE
7$382,036$121,213.91$30,118$1,347.30+$351.9KAVTE
8$586,325$177,546.69$35,505$1,652.97+$550.8KAVTE
9$882,029$254,661.46$41,940$2,031.88+$840.1KAVTE
10$1,301,805$358,033.82$49,643$2,502.61+$1.25MAVTE

AVTE vs PM: Complete Analysis 2026

AVTEStock

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Full AVTE Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this AVTE vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVTE vs SCHDAVTE vs JEPIAVTE vs OAVTE vs KOAVTE vs MAINAVTE vs MOAVTE vs BTIAVTE vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.